157 related articles for article (PubMed ID: 37723659)
1. Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion.
Li T; Tian P; Huang Q; Zeng H; Wei Q; Li Y
Clin Respir J; 2023 Nov; 17(11):1158-1168. PubMed ID: 37723659
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
3. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
Clive AO; Kahan BC; Hooper CE; Bhatnagar R; Morley AJ; Zahan-Evans N; Bintcliffe OJ; Boshuizen RC; Fysh ET; Tobin CL; Medford AR; Harvey JE; van den Heuvel MM; Lee YC; Maskell NA
Thorax; 2014 Dec; 69(12):1098-104. PubMed ID: 25100651
[TBL] [Abstract][Full Text] [Related]
4. Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.
Li Q; Hu C; Su S; Ma Z; Geng Y; Hu Y; Jin H; Li H; Lu B
Cancer Med; 2023 Jul; 12(14):14949-14959. PubMed ID: 37288833
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
6. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
Gayaf M; Anar C; Canbaz M; Doğan Bİ; Erbaycu AE; Güldaval F
Tuberk Toraks; 2021 Jun; 69(2):133-143. PubMed ID: 34256503
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
Lee YS; Nam HS; Lim JH; Kim JS; Moon Y; Cho JH; Ryu JS; Kwak SM; Lee HL
BMC Cancer; 2017 Aug; 17(1):557. PubMed ID: 28830378
[TBL] [Abstract][Full Text] [Related]
10. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
11. An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore.
Abisheganaden J; Verma A; Dagaonkar RS; Light RW
Respiration; 2018; 96(4):308-313. PubMed ID: 29945142
[TBL] [Abstract][Full Text] [Related]
12. The prognosis after contraindicated surgery of NSCLC patients with malignant pleural effusion (M1a) may be better than expected.
Ren Y; Dai C; Shen J; Liu Y; Xie D; Zheng H; He J; Liang W; Jiang G; Fei K; Yang P; He J; Chen C
Oncotarget; 2016 May; 7(18):26856-65. PubMed ID: 27057627
[TBL] [Abstract][Full Text] [Related]
13. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
14. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
Thompson JC; Fan R; Black T; Yu GH; Savitch SL; Chien A; Yee SS; Sen M; Hwang WT; Katz SI; Feldman M; Vachani A; Carpenter EL
Lung Cancer; 2019 Jan; 127():25-33. PubMed ID: 30642547
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors of Malignant Pleural Effusion among Palliative Care Outpatients: A Retrospective Study.
Jeba J; Cherian RM; Thangakunam B; George R; Visalakshi J
Indian J Palliat Care; 2018; 24(2):184-188. PubMed ID: 29736123
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion.
Takeuchi E; Okano Y; Machida H; Atagi K; Kondou Y; Kadota N; Hatakeyama N; Naruse K; Shinohara T
Cancer Immunol Immunother; 2022 Feb; 71(2):365-372. PubMed ID: 34170380
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.
Shi XY; Yi FS; Wang Z; Qiao X; Zhai K
Thorac Cancer; 2020 Feb; 11(2):320-328. PubMed ID: 31837116
[TBL] [Abstract][Full Text] [Related]
19. Clinical predictors and outcomes of non-expandable lung following percutaneous catheter drainage in lung cancer patients with malignant pleural effusion.
Kim CH; Park JE; Cha JG; Park J; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Lim JK; Lee J
Medicine (Baltimore); 2023 Jun; 102(26):e34134. PubMed ID: 37390258
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
